Aventis Pharmaceuticals successfully defends against monopolization claims based on fraud on the Patent Office theory
Clients sanofi-aventis S.A.
Jones Day resolved class action claims that Aventis Pharmaceuticals, the exclusive licensee of patents covering DDAVP (a treatment for certain water metabolism disorders), knew that the licensor obtained those patents by fraud before the Patent and Trademark Office.
In re DDAVP Direct Purchaser Antitrust Litigation, 585 F.3d 677 (2d Cir. 2009); No. 05-cv-2237 (S.D.N.Y. 2006)